A2002 |
Nivolumab (anti-PD-1)
|
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
-
Cancer Cell, 2024, S1535-6108(24)00080-1
-
Nat Genet, 2024, 10.1038/s41588-024-01948-8
-
Nat Commun, 2024, 15(1):8609
|
|
A2004 |
Atezolizumab (anti-PD-L1)
|
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
-
Nat Commun, 2024, 15(1):9723
-
J Immunother Cancer, 2024, 12(5)e008669
-
Cell Death Dis, 2024, 15(2):175
|
|
A2005 |
Pembrolizumab (anti-PD-1)
|
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
-
Nat Med, 2024, 10.1038/s41591-024-02824-y
-
Cell Mol Immunol, 2024, 21(1):60-79
-
Cell Rep Med, 2024, S2666-3791(24)00196-4
|
|
S7912 |
BMS202
|
BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
|
-
Phytomedicine, 2024, 125:155370
-
J Med Chem, 2024, 67(5):4036-4062
-
Mar Drugs, 2024, 22(7)303
|
|
A2013 |
Durvalumab (anti-PD-L1)
|
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
-
J Biol Chem, 2024, S0021-9258(24)01826-X
-
Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
-
Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
|
|
S7911 |
BMS-1
|
BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. |
-
J Med Chem, 2024, 67(5):4036-4062
-
PLoS Comput Biol, 2024, 20(11):e1012284
-
Int. J. Mol. Sci, 2023, 24(4)
|
|
S8158 |
PD-1/PD-L1 Inhibitor 3
|
PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM |
-
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
-
J Med Chem, 2024, 67(5):4036-4062
-
Pharmaceuticals (Basel), 2023, 16(7)1051
|
|
S8275 |
Tomivosertib (eFT-508)
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
-
J Clin Invest, 2024, 134(16)e168393
-
Sci Adv, 2024, 10(37):eadi7673
-
PLoS Biol, 2023, 21(8):e3002227
|
|
S8859 |
BMS-1166
|
BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. |
-
Life Sci Alliance, 2024, 10.26508/lsa.202302461
-
Biomed Res, 2024, 45(5):179-186
-
Int J Biol Sci, 2023, 19(14):4627-4643
|
|
S8549 |
AUNP-12
|
AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
-
Acta Pharm Sin B, 2024, 14(1):350-364
-
Carcinogenesis, 2022, bgac043
-
Molecules, 2019, 24(15)
|
|
A2015 |
Avelumab (anti-PD-L1)
|
Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa. |
-
J Biol Chem, 2024, S0021-9258(24)01826-X
-
Viruses, 2021, 13(10)2017
|
|
A2115 |
Anti-mouse PD-L1 (B7-H1)-InVivo
|
Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80). |
-
Cancer Commun (Lond), 2024, 10.1002/cac2.12545
-
Cancer Commun (Lond), 2024, 44(6):670-694
-
Biomaterials, 2024, 312:122714
|
|
S0094 |
SR 0987
|
SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. |
-
Evid Based Complement Alternat Med, 2022, 2022:8315503
|
|
A2017 |
Spartalizumab (anti-PD-1)
|
Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. |
-
Elife, 2020, 9
|
|
E1322 |
GS-4224
|
GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. |
|
|
A2381 |
Serplulimab (Anti-PDCD1 / PD-1 / CD279)
|
Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. |
|
|
A2835 |
Dostarlimab (Anti-PDCD1 / PD-1 / CD279)
|
Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD. |
|
|
A2165New |
Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo
|
Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
|
|
A2156New |
Anti-human PD-L1 (B7-H1)-InVivo
|
Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. |
|
|
S8473 |
CA-170 (AUPM-170)
|
CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. |
|
|
A2858 |
Finotonlimab (Anti-PDCD1 / PD-1 / CD279)
|
Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD. |
|
|
A2022 |
Cemiplimab (anti-PD-1)
|
Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. |
-
Life Sci Alliance, 2024, 7(3)e202302368
|
|
A2613 |
Anti-B7-H1 / PD-L1 / CD274 (MDX-1105)
|
Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD. |
|
|
A2882 |
Geptanolimab (Anti-PDCD1 / PD-1 / CD279)
|
Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD. |
|
|
A2913 |
Iparomlimab (Anti-PDCD1 / PD-1 / CD279)
|
Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. |
|
|
A2122 |
Anti-mouse PD-1 (CD279)-InVivo
|
Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
-
J Immunother Cancer, 2024, 12(8)e009024
-
Cancer Lett, 2024, 588:216814
-
Cell Rep, 2024, 43(11):114962
|
|
A2923 |
Lodapolimab (Anti-B7-H1 / PD-L1 / CD274)
|
Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. |
|
|
A2956 |
Nofazinlimab (Anti-PDCD1 / PD-1 / CD279)
|
Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. |
|
|
A2998 |
Opucolimab (Anti-B7-H1 / PD-L1 / CD274)
|
Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD. |
|
|
S9610 |
BMS-1001
|
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. |
|
|
E3151 |
Sanguisorbae Radix Extract
|
Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects. |
|
|
A2035 |
Sintilimab (anti-PD-1)
|
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. |
-
J Immunother Cancer, 2024, 12(9)e009603
|
|
S9863 |
INCB086550
|
INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. |
|
|
A2775 |
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. |
|
|
A2778 |
Garivulimab (Anti-B7-H1 / PD-L1 / CD274)
|
Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD. |
|
|
A2780 |
Manelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD. |
|
|
A2781 |
Pacmilimab (Anti-B7-H1 / PD-L1 / CD274)
|
Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD. |
|
|
A2782 |
Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274)
|
Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. |
|
|
A2783 |
Sugemalimab (Anti-B7-H1 / PD-L1 / CD274)
|
Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD. |
|
|
A2016 |
Camrelizumab (anti-PD-1)
|
Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. |
-
Life Sci Alliance, 2024, 7(3)e202302368
|
|
A2811 |
Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD. |
|
|
S7912 |
BMS202
|
BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
|
- Phytomedicine, 2024, 125:155370
- J Med Chem, 2024, 67(5):4036-4062
- Mar Drugs, 2024, 22(7)303
|
|
S7911 |
BMS-1
|
BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. |
- J Med Chem, 2024, 67(5):4036-4062
- PLoS Comput Biol, 2024, 20(11):e1012284
- Int. J. Mol. Sci, 2023, 24(4)
|
|
S8158 |
PD-1/PD-L1 Inhibitor 3
|
PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM |
- ACS Appl Mater Interfaces, 2024, 16(18):22839-49
- J Med Chem, 2024, 67(5):4036-4062
- Pharmaceuticals (Basel), 2023, 16(7)1051
|
|
S8275 |
Tomivosertib (eFT-508)
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
- J Clin Invest, 2024, 134(16)e168393
- Sci Adv, 2024, 10(37):eadi7673
- PLoS Biol, 2023, 21(8):e3002227
|
|
S8859 |
BMS-1166
|
BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. |
- Life Sci Alliance, 2024, 10.26508/lsa.202302461
- Biomed Res, 2024, 45(5):179-186
- Int J Biol Sci, 2023, 19(14):4627-4643
|
|
S8549 |
AUNP-12
|
AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
- Acta Pharm Sin B, 2024, 14(1):350-364
- Carcinogenesis, 2022, bgac043
- Molecules, 2019, 24(15)
|
|
S0094 |
SR 0987
|
SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. |
- Evid Based Complement Alternat Med, 2022, 2022:8315503
|
|
E1322 |
GS-4224
|
GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. |
|
|
S8473 |
CA-170 (AUPM-170)
|
CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. |
|
|
S9610 |
BMS-1001
|
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. |
|
|
E3151 |
Sanguisorbae Radix Extract
|
Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects. |
|
|
S9863 |
INCB086550
|
INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. |
|
|
A2002 |
Nivolumab (anti-PD-1)
|
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
- Cancer Cell, 2024, S1535-6108(24)00080-1
- Nat Genet, 2024, 10.1038/s41588-024-01948-8
- Nat Commun, 2024, 15(1):8609
|
|
A2004 |
Atezolizumab (anti-PD-L1)
|
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
- Nat Commun, 2024, 15(1):9723
- J Immunother Cancer, 2024, 12(5)e008669
- Cell Death Dis, 2024, 15(2):175
|
|
A2005 |
Pembrolizumab (anti-PD-1)
|
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
- Nat Med, 2024, 10.1038/s41591-024-02824-y
- Cell Mol Immunol, 2024, 21(1):60-79
- Cell Rep Med, 2024, S2666-3791(24)00196-4
|
|
A2013 |
Durvalumab (anti-PD-L1)
|
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
- J Biol Chem, 2024, S0021-9258(24)01826-X
- Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
- Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
|
|
A2015 |
Avelumab (anti-PD-L1)
|
Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa. |
- J Biol Chem, 2024, S0021-9258(24)01826-X
- Viruses, 2021, 13(10)2017
|
|
A2115 |
Anti-mouse PD-L1 (B7-H1)-InVivo
|
Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80). |
- Cancer Commun (Lond), 2024, 10.1002/cac2.12545
- Cancer Commun (Lond), 2024, 44(6):670-694
- Biomaterials, 2024, 312:122714
|
|
A2017 |
Spartalizumab (anti-PD-1)
|
Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. |
- Elife, 2020, 9
|
|
A2381 |
Serplulimab (Anti-PDCD1 / PD-1 / CD279)
|
Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. |
|
|
A2835 |
Dostarlimab (Anti-PDCD1 / PD-1 / CD279)
|
Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD. |
|
|
A2165New |
Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo
|
Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
|
|
A2156New |
Anti-human PD-L1 (B7-H1)-InVivo
|
Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. |
|
|
A2858 |
Finotonlimab (Anti-PDCD1 / PD-1 / CD279)
|
Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD. |
|
|
A2022 |
Cemiplimab (anti-PD-1)
|
Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. |
- Life Sci Alliance, 2024, 7(3)e202302368
|
|
A2613 |
Anti-B7-H1 / PD-L1 / CD274 (MDX-1105)
|
Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD. |
|
|
A2882 |
Geptanolimab (Anti-PDCD1 / PD-1 / CD279)
|
Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD. |
|
|
A2913 |
Iparomlimab (Anti-PDCD1 / PD-1 / CD279)
|
Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. |
|
|
A2122 |
Anti-mouse PD-1 (CD279)-InVivo
|
Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
- J Immunother Cancer, 2024, 12(8)e009024
- Cancer Lett, 2024, 588:216814
- Cell Rep, 2024, 43(11):114962
|
|
A2923 |
Lodapolimab (Anti-B7-H1 / PD-L1 / CD274)
|
Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. |
|
|
A2956 |
Nofazinlimab (Anti-PDCD1 / PD-1 / CD279)
|
Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. |
|
|
A2998 |
Opucolimab (Anti-B7-H1 / PD-L1 / CD274)
|
Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD. |
|
|
A2035 |
Sintilimab (anti-PD-1)
|
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. |
- J Immunother Cancer, 2024, 12(9)e009603
|
|
A2775 |
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. |
|
|
A2778 |
Garivulimab (Anti-B7-H1 / PD-L1 / CD274)
|
Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD. |
|
|
A2780 |
Manelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD. |
|
|
A2781 |
Pacmilimab (Anti-B7-H1 / PD-L1 / CD274)
|
Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD. |
|
|
A2782 |
Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274)
|
Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. |
|
|
A2783 |
Sugemalimab (Anti-B7-H1 / PD-L1 / CD274)
|
Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD. |
|
|
A2016 |
Camrelizumab (anti-PD-1)
|
Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. |
- Life Sci Alliance, 2024, 7(3)e202302368
|
|
A2811 |
Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD. |
|
|